The Effects of Erythromycin in Patients Treated with Cyclosporine
- RAFAEL MARTELL, M.D.;
- DAVID HEINRICHS, M.D.;
- CALVIN R. STILLER, M.D.;
- MORRIS JENNER, M.D.;
- PAUL A. KEOWN, M.B., Ch.B.; and
- JOHN DUPRE, M.D.
Excerpt
The clinical introduction of cyclosporine heralded a new class of immunoregulatory drugs with specific inhibitory effects on T-cell functions and elaborated products (1, 2). Cyclosporine's role in facilitating solid organ transplantation and altering autoimmune responses continues to grow (3). As use of the drug widens, more interactions with other pharmacologic agents will be reported. We report the cases of three patients in a pilot study of the effect of cyclosporine in type 1 diabetes (4) in whom treatment with erythromycin was associated with acutely elevated trough serum levels of cyclosporine and clinical manifestations of acute drug toxicity.
No other drugs
This 100-word excerpt has been provided in the absence of an abstract.
Acknowledgments
ACKNOWLEDGMENTS: The authors thank Sandoz Pharmaceuticals, Ltd. , Dorval, Canada, for supplying the cyclosporine and the radioimmunoassay kits; and M. Staweki, J. McMichael, and C. Burley for their technical assistance.
Article and Author Information
-
▸Requests for reprints should be addressed to Rafael Martell, M.D.; Department of Nephrology and Transplantation, University Hospital, P.O. Box 5339, Station A; London, Ontario, N6A 5A5, Canada.
Most Read
